SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (844)4/28/1999 2:20:00 PM
From: Gary Mohilner  Read Replies (1) | Respond to of 1073
 
I couldn't find the article at the sight you posted, but thank you as I did subscribe. Perhaps they'll add it later, or I may have not search properly.

In the article, do you remember if they considered ImmunoGen's method of humanizing. To my knowledge it's not very well known, but should prove itself shortly in the huC242-DM1 drug that should be in Phase 1 trials by Summer.

Thanks,

Gary Mohilner



To: scaram(o)uche who wrote (844)4/28/1999 2:46:00 PM
From: RCMac  Respond to of 1073
 
Thanks, Rick,

The Jim Kling article you mention is apparently not on line. If you go to URL in your post, then click on "Table of Contents" the article is mentioned, but not hyperlinked.

Incidentally, the Viagra artlcle, highlighted on the page your link gives us, is also by Jim Kling. Clicking on his byline links us to his home page, which in turn has links to a number of other articles by him.

I've subscribed, and look forward to the journal. Again, thanks.

-- Bob


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News